Core Insights - The European Commission has approved a new 7.2mg weekly maintenance dose of Wegovy (semaglutide injection) for adult obesity patients, providing doctors with a new treatment option for patients needing further weight loss after using the 2.4mg dose [1] - The approval is based on a positive review from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) [1] - Wegovy 7.2mg has already been approved and launched in the UK, with applications under review by the FDA and other regulatory bodies in various countries [1] Group 1: Approval and Dosage - The new 7.2mg dose allows for a single injection of three 2.4mg doses weekly, enabling patients to achieve greater weight loss while maintaining muscle function after at least four weeks on the 2.4mg dose [1] - Novo Nordisk has submitted a marketing authorization application for the 7.2mg single-dose injection pen in the EU, with potential approval and market launch expected this year [1] Group 2: Clinical Study Results - Two clinical studies, STEP UP (1,407 participants) and STEP UP T2D (512 participants), showed that participants receiving the 7.2mg dose with lifestyle interventions lost significantly more weight than those on placebo [2] - In non-diabetic adult obesity participants, the Wegovy 7.2mg group achieved an average weight loss of 21%, compared to approximately 2% in the placebo group [3] - About one-third of participants experienced a weight reduction of 25% or more, with 84% of the weight loss attributed to fat mass reduction while preserving muscle function [3] Group 3: Side Effects and Expert Commentary - The most common adverse reactions included nausea, diarrhea, vomiting (24.8%), and abnormal sensations (22.9%), which were generally mild to moderate and transient [3] - The executive vice president of Novo Nordisk emphasized that this approval represents a significant advancement in helping the obese population achieve more substantial weight loss and offers greater flexibility for healthcare professionals in creating individualized treatment plans [3]

Core Viewpoint - The World Health Organization (WHO) is developing new guidelines for the treatment of adult obesity based on GLP-1 therapies, set to be officially released in September 2025, marking a significant policy shift in addressing the global obesity crisis [1] Group 1: Guidelines Development - The guidelines are being created by an independent guideline development group (GDG) consisting of experts in obesity, epidemiology, clinical management, pharmacology, health economics, public health programs, and policymakers to ensure adherence to WHO's strict standards [1] - The purpose of the guidelines is to clarify the clinical indications, applications, and planning considerations for GLP-1 receptor agonists (GLP1RAs) [1] Group 2: Implications - This will be the first time the WHO officially recommends the use of weight-loss medications for treating adult obesity, indicating a major shift in the organization's approach to the obesity crisis [1]